Vercise (system of stimulation of a brain)

2020: Announcement of Vercise Genus

In the middle of September, 2020 the Boston Scientific company released the system of deep stimulation of a brain of fourth generation Vercise Genus. It is compatible to MRT of all body and is intended for treatment of symptoms of Parkinson's disease, an essentsialny tremor and dystonia by electric stimulation of certain parts of a brain.

Vercise Genus is supplied with new software which optimizes possibilities of programming under control of visualization thanks to exclusive cooperation of Boston Scientific with Brainlab. Among other things Vercise Genus can be programmed far off through Bluetooth that is of particular importance during an era of social distancing.

Boston Scientific provided a system for deep stimulation of a brain

Indications include application of a new system for one-sided or bilateral stimulation of a subtalamichesky core or an internal pale ball for treatment of the Parkinson's disease sensitive to a levodopa, but without sufficient pharmacological control and also for treatment of primary and secondary dystonia hard to cure at persons from seven-year age. Talamichesky stimulation using the Vercise Genus system is shown for suppression of a tremor which is not controlled by drugs, at patients with an essentsialny tremor or Parkinson's disease.

The Vercise Genus DBS system was built in in a row devices, small, convenient for patients, which provide remote programming of therapy, - the senior vice president of Boston Scientific for neuromodulation Maulik Nanavaty noted. - Besides, the rechargeable battery provides service of the device within 25 years, and software of a system is compatible to MRT so patients can pick up to themselves the option corresponding to individual requirements.

The Boston Scientific company provided limited European release of a new system after approval of regulatory bodies.^[1]

2019: Announcement

At the beginning of February, 2019 the Boston Scientific company put on the market two new systems of deep stimulation of a brain (DBS) for treatment of Parkinson's disease.

DBS is used at Parkinson's disease more than 25 years and includes soft electrostimulation of implants in target area of a brain. The company provided the new systems which use eight individually controlled electrodes on each assignment and adapt to changes of an impedance. Such characteristics provide more exact stimulation of cages targets and reduce the probability of ghost effects, thereby increasing satisfaction of patients.

Boston Scientific released the systems of deep stimulation of a brain for treatment of Parkinson's disease

The rechargeable Vercise Gevia system is expected battery service life not less than 15 years, and not rechargeable Vercise Primary Cell system with the same characteristics of stimulation should serve not less than three years. Both systems are connected to software which allows the doctor to visualize stimulation distribution. Boston Scientific claims that both DBS systems are included in the global register of post-marketing and other clinical trials which keep track of efficiency and security of devices.

The pro forma income statement of Boston Scientific showed that the division of neuromodulation in 2018 earned $780 million, i.e. is 22% more, than in 2017. Some sceptics consider that negative perception by patients of methods of electrostimulation can lower revenues of the company. Nevertheless, Boston Scientific considers that by 2022 neuromodulation can generate revenue in the amount of $1 billion. The producer is going to expand indications for DBS by 2023.

Among competitors of Boston Scientific the Abbott Laboratories company which in 2017 strengthened the positions in the market thanks to acquisition of St. Jude Medical and the Infinity DBS system, and Medtronic company which intends to expand the offer of DBS within group of recovery methods of treatment and to start on the market the new system of deep stimulation of a brain after 2020 are selected.^[2]

Notes